OPTN
vs
S&P 500
OPTN
S&P 500
Over the past 12 months, OPTN has significantly outperformed S&P 500, delivering a return of +60% compared to the S&P 500's +13% growth.
Stocks Performance
OPTN vs S&P 500
Performance Gap
OPTN vs S&P 500
Performance By Year
OPTN vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
OptiNose Inc
Glance View
OptiNose, Inc. operates as a pharmaceutical company. The company is headquartered in Yardley, Pennsylvania and currently employs 189 full-time employees. The company went IPO on 2017-10-13. The firm's first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 micrograms (mcg), is a therapeutic utilizing the Company's Exhalation Delivery System (EDS), which delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps. The Onzetra Xsail is a sumatriptan nasal powder and sells in the United States, Canada and Mexico.